国投证券股份有限公司 关于上海雪榕生物科技股份有限公司 2023 年度募集资金存放与使用情况的专项核查报告 根据《证券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市 规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》 等有关规定，国投证券股份有限公司（以下简称"国投证券"或"本保荐机构"） 作为上海雪榕生物科技股份有限公司（以下简称"雪榕生物"或"公司"）创业 板向特定对象发行股票的保荐机构，对雪榕生物 2023 年度募集资金存放和使用 情况进行了专项核查，现将核查情况报告如下： 一、募集资金基本情况 经中国证监会《关于同意上海雪榕生物科技股份有限公司向特定对象发行股 票注册的批复》（证监许可【2021】881 号）核准，公司于 2022 年 3 月 4 日向 11 名特定对象发行人民币普通股（A 股）65,676,567 股，发行价格为人民币 6.06 元 /股，募集资金总额为人民币 397,999,996.02 元，扣除与本次发行有关费用人民币 10,519,671.82 元（含增值税）后，实际 ...

Financial Performance - The company achieved operating revenue of CNY 2,062.83 million in 2021, a decrease of 6.33% year-on-year[13]. - The net profit attributable to shareholders was CNY -292.07 million, representing a decline of 226.76% compared to the previous year[13]. - The net profit after deducting non-recurring gains and losses was -¥29.0 million in 2021, a decrease of 230.53% compared to a profit of ¥22.2 million in 2020[30]. - The weighted average return on net assets was -15.88%, a decrease of 28.41% from the previous year[20]. - The company's total assets decreased by 4.57% to CNY 4,340.13 million at the end of 2021[19]. - The net cash flow from operating activities was CNY 246.75 million, down 55.58% from the previous year[20]. - The net profit attributable to shareholders was ¥101.4 million in Q1, but turned negative in subsequent quarters, with Q2 at -¥172.1 million, Q3 at -¥44.7 million, and Q4 at -¥176.7 million[21]. - The net cash flow from operating activities showed a significant recovery, with Q1 at ¥94.2 million, Q3 at ¥19.2 million, and Q4 surging to ¥175.8 million[21]. - The asset-liability ratio increased to 61.88% in 2021 from 55.89% in 2020, indicating a rise of 5.99%[30]. - The EBITDA to total debt ratio fell to 2.43% in 2021 from 23.90% in 2020, reflecting a decline of 21.47%[30]. - The interest coverage ratio dropped significantly to -2.84 in 2021 from 3.28 in 2020, a decrease of 186.59%[30]. Dividend and Shareholder Information - The company reported a cash dividend of 0.00 yuan per 10 shares for all shareholders, with no bonus shares issued, based on a total of 507,600,151 shares[1]. - The top shareholder, Yang Yongping, holds 24.29% of the shares, amounting to 107,365,050 shares[22]. - The company has no preferred shareholders as of the report date[24]. Business Operations and Strategy - The company operates modern agricultural enterprises focused on the research, cultivation, and sales of edible mushrooms, with production facilities in multiple regions including Jilin, Shandong, Guangdong, Sichuan, Guizhou, Gansu, and Thailand[3]. - Key products include Enoki mushrooms, King oyster mushrooms, Shiitake mushrooms, and others, emphasizing high quality and safety in food production[5]. - The sales model primarily involves distributors, with direct sales to supermarkets, chain restaurants, and fresh food delivery platforms, utilizing a buyout sales approach[9]. - The pricing strategy includes weekly market analysis for existing products and comprehensive market research for new product pricing, ensuring competitive positioning[10]. - The company has implemented a credit policy for large and quality customers, resulting in low accounts receivable balances[10]. - The company emphasizes the mechanization, standardization, and year-round production of edible mushrooms, significantly saving land resources[3]. - The company aims to enhance its market presence through continuous product innovation and expansion into new regions[3]. - The company has established a nationwide sales network to enhance market responsiveness and customer retention[17]. - The competitive landscape in the edible mushroom industry has intensified, leading to a general decline in profitability across the sector in 2021[17]. Audit and Compliance - The company has transitioned its auditing firm to Ernst & Young Huaming, receiving a standard unqualified audit opinion for the financial report[1]. Project Losses - The company reported a significant loss of CNY 4,850.09 million from its Thailand project, with a loss attributable to shareholders of CNY 2,910.05 million[13]. Quarterly Performance - In Q1 2021, the company reported revenue of ¥566.5 million, while Q2 revenue dropped to ¥362.3 million, followed by Q3 at ¥500.5 million, and Q4 at ¥633.5 million[21].

Financial Performance - The company's revenue for Q1 2021 was ¥566,499,913.52, a decrease of 5.72% compared to ¥600,852,768.17 in the same period last year[8] - Net profit attributable to shareholders was ¥101,367,147.34, down 40.30% from ¥169,805,933.35 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥84,346,680.30, reflecting a 51.98% decline from ¥175,658,147.06 in the previous year[8] - Basic earnings per share decreased by 40.00% to ¥0.24 from ¥0.40 in the previous year[8] - Diluted earnings per share fell by 45.00% to ¥0.22, down from ¥0.40 year-on-year[8] - The weighted average return on equity was 4.90%, down 4.40% from 9.30% in the same period last year[8] - The total comprehensive income for Q1 2021 was CNY 93,107,824.21, a decrease of 42.55% from CNY 162,024,727.12 in Q1 2020[52] - The operating profit for Q1 2021 was CNY 88,914,090.49, down 47.36% from CNY 168,939,525.68 in the same period last year[54] Cash Flow and Assets - The net cash flow from operating activities was ¥94,171,489.26, a significant drop of 55.16% compared to ¥210,012,722.59 in the same quarter last year[8] - Cash and cash equivalents decreased by 40.50% to 452.10 million yuan, primarily due to loan repayments and funding for investment projects[18] - The company's cash flow from operating activities for Q1 2021 was CNY 94,171,489.26, a significant decrease of 55.19% compared to CNY 210,012,722.59 in Q1 2020[59] - Total assets at the end of the reporting period were ¥4,523,132,192.42, a slight decrease of 0.54% from ¥4,547,783,435.53 at the end of the previous year[8] - Total cash and cash equivalents at the end of the period amounted to 455,792,498.39 CNY, down from 510,734,470.23 CNY in the previous period[60] Expenses and Costs - Total operating costs increased to CNY 497,618,778.68 from CNY 434,113,698.18, with operating costs specifically rising to CNY 432,067,920.20 from CNY 368,984,797.21[50] - Research and development expenses increased by 58.03% to 47.59 million yuan, reflecting higher investment in R&D activities[18] - The financial expenses for Q1 2021 were CNY 10,871,686.12, which is a significant increase compared to CNY 4,819,068.21 in Q1 2020[54] - The company reported a decrease in sales expenses to CNY 3,618,995.52 from CNY 5,186,929.58 in the previous year, reflecting a reduction of 30.29%[54] Market and Competition - The company anticipates intensified market competition leading to potential price declines in its products, prompting a strategy to enhance marketing efforts and brand recognition[20][21] - The company faces risks of declining gross margin and profits due to increased competition in the domestic edible mushroom market and potential underperformance of its overseas production base in Thailand[23] Investments and Projects - The company established a joint venture, Shanghai Rongshang Food Co., Ltd., with a 60% ownership stake, to enhance its market presence[27] - The project for the Thai edible mushroom factory has not yet commenced, with no funds allocated to it so far[31] - The company has achieved 62.93% of the investment progress for the Dezhou daily production project, with 6.67 million RMB invested out of 25 million RMB planned[31] Regulatory Compliance - The company received approval from the China Securities Regulatory Commission for a specific stock issuance, indicating compliance with regulatory requirements[28] - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[35] - There were no violations regarding external guarantees during the reporting period[34] Risks and Challenges - Seasonal fluctuations in sales prices and profits are expected, with the first and fourth quarters typically yielding higher prices due to increased demand[22] - The main raw materials, including rice bran and corn husks, are subject to quality and price fluctuations, which could adversely affect the company's gross margin if not managed effectively[24] - Despite a controlled cultivation model ensuring food safety, there are still risks of contamination during raw material procurement and inventory management[26] - The expansion of production capacity and business scale may lead to management risks, prompting the company to implement a partner mechanism to enhance management efficiency[25]

上海雪榕生物科技股份有限公司 募集资金存放与使用情况鉴证报告 2023年度 上海雪榕生物科技股份有限公司 目 录 | | | 页 次 | | --- | --- | --- | | 一、 | 关于上海雪榕生物科技股份有限公司 | | | | 2023年度募集资金存放与使用情况专项鉴证报告 | 1 - 2 | | 二、 | 上海雪榕生物科技股份有限公司 | | | | 关于2023年度募集资金存放与使用情况的专项报告 | 3 - 12 | 关于上海雪榕生物科技股份有限公司 2023年度募集资金存放与使用情况鉴证报告 安永华明（2024）专字第70009152_B02号 上海雪榕生物科技股份有限公司 上海雪榕生物科技股份有限公司董事会： 我们接受委托，对后附的上海雪榕生物科技股份有限公司2023年度募集资金存放 与使用情况的专项报告（"募集资金专项报告"）进行了鉴证。按照《上市公司监管 指引第2号——上市公司募集资金管理和使用的监管要求》、《深圳证券交易所上市公 司自律监管指引第2号——创业板上市公司规范运作》及相关格式指南编制募集资金专 项报告，并保证其内容真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏 ...

一、董事会会议召开情况 | 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-025 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 第五届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 1、本次董事会由董事长杨勇萍先生召集，会议通知于 2024 年 4 月 12 日以 电子邮件等通讯方式发出。 2、本次董事会于 2024 年 4 月 25 日在上海雪榕生物科技股份有限公司（以 下简称"公司"）会议室召开，采取现场和通讯相结合的方式进行表决。 3、本次会议应出席董事 7 人，实际出席董事 7 人。 4、本次董事会由董事长杨勇萍先生主持，公司监事、高级管理人员和公司 保荐代表人聂晓春女士、黄璇女士列席了本次董事会。 5、本次董事会会议的召集、召开和表决程序符合《公司法》等法律、法规 及《公司章程》的有关规定，合法有效。 二、董事会会议审议情况 1、审议通过《关于 2023 年总经理工作报告的议案》 本议案以 7 票同意，0 票反对，0 票弃权获得通过 ...

| 证券代码：300511 | 证券简称：雪榕生物 公告编号：2024-036 | | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | 上海雪榕生物科技股份有限公司 关于变更注册资本及修订《公司章程》的公告 | 条目 | 原条款 | 修订后条款 | | --- | --- | --- | | 第六条 | 公司注册资本为人民币 49,878.0598 | 公司注册资本为人民币 49,878.0885 | | | 万元。 | 万元。 | | | 经中国证监会证监许可[2016]539 | 经中国证监会证监许可[2016]539 | | --- | --- | --- | | | 号文核准，公司首次向社会公众公 | 号文核准，公司首次向社会公众公 万股，于 | | | 开发行人民币普通股 3,750 万股，于 | 开发行人民币普通股 3,750 | | | 2016 年 5 月 4 日在深圳证券交易所 | 2016 年 5 月 4 日在深圳证券交易所 | | | 创业板上市。 | 创业板上市。 | | | 公司股票被终止上市后，将直接退 | 公司股票被终止上市后，将直接退 | | 第 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-040 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 2024 年 4 月 26 日 上海雪榕生物科技股份有限公司（ 以下简称"公司"）董事会根据（ 上市公司 独立董事管理办法》 深圳证券交易所上市公司自律监管指引第 2 号——创业板 上市公司规范运作》等要求，并结合公司在任独立董事黄建春先生、李学尧先生、 李丹蒙先生分别出具的（ 独立董事独立性自查情况表》，对三位独立董事的独立 性情况进行了评估，并出具如下意见： 经核查独立董事黄建春先生、李学尧先生、李丹蒙先生的任职经历以及出具 的（ 独立董事独立性自查情况表》，上述人员不存在任何妨碍其进行独立客观判 断的关系，不存在影响独立董事独立性的情况，符合（ 上市公司独立董事管理办 法》 深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》中关于独立董事的任职资格及独立性的要求。 特此公告。 上海雪榕生物科技股份有限公司 董 事 会 上海雪榕生物科技股份有限公司 董事会关于独立董事独立性情况的专项意见 本公司及 ...

| 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-039 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 为充分尊重投资者、提升交流的针对性，现就公司 2023 年度业绩说明会提 前向投资者公开征集问题，广泛听取投资者的意见和建议。投 资 者 可 提 前 登 录"互动易"平台（http://irm.cninfo.com.cn）"云访谈"栏目进入公司本次年度业 绩说明会页面进行提问。届时公司将在本次说明会上对投资者普遍关注的问题进 行回答。此次活动交流期间，投资者仍可登陆活动界面进行互动提问。 欢迎广大投资者积极参与。 特此公告。 上海雪榕生物科技股份有限公司 董事会 关于举行 2023 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"） 已于 2024 年 4 月 26 日在巨潮资讯网（http://www.cninfo.com.cn）上披露了公司的《2023 年年度报告》 及《2023 年年度报告摘要》。 ...

上海雪榕生物科技股份有限公司 2023年度内部控制自我评价报告 2023年12月31日 上海雪榕生物科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管 要求（以下简称"企业内部控制规范体系"），结合上海雪榕生物科技股份有限公 司及子公司（以下简称"本公司"）内部控制制度和评价办法，在内部控制日常监 督和专项监督的基础上，对本公司2023年12月31日（内部控制评价报告基准日） 的内部控制有效性进行评价。 第一部分：本公司基本情况 上海心向榕食品有限公司，注册资本为人民币1,500万元； 雪榕生物科技（泰国）有限公司，注册资本为泰铢100,000万铢； Kaset Thai Sustainable Company Limited，注册资本为泰铢11,300万铢。 本公司经营范围为：一般项目：技术服务、技术开发、技术咨询、技术交流、 技术转让、技术推广；食用菌种植；食用农产品初加工；食用农产品批发；食用 农产品零售；初级农产品收购；农林牧副渔业专业机械的制造；农、林、牧、副、 渔业专业机械的销售；农林牧副渔业专业机械的安装、维修；仪器仪表销售；非 居住房地产租赁；货物进出 ...

上海雪榕生物科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 上海雪榕生物科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召 开第五届董事会第九次会议和第五届监事会第七次会议，审议通过了《关于会计 政策变更的议案》。本次会计政策变更系公司根据法律法规和国家统一的会计制 度的要求进行的变更，无需提交公司股东大会审议，现将本次会计政策变更的相 关事项公告如下： | 证券代码：300511 | 证券简称：雪榕生物 | 公告编号：2024-035 | | --- | --- | --- | | 债券代码：123056 | 债券简称：雪榕转债 | | 一、本次会计政策变更情况概述 1、变更原因 2023 年 10 月 25 日，中华人民共和国财政部（以下简称"财政部"）发布了 《企业会计准则解释第 17 号》（财会〔2023〕21 号），规定了"关于流动负债 与非流动负债的划分"、"关于供应商融资安排的披露"、"关于售后租回交易 的会计处理"等内容，以上自 2024 年 1 月 1 日起施行。 2、变更日期 ...